Lipoprotein Lipase 1595 C/G and Hepatic Lipase –480 C/T Polymorphisms – Impact on Lipid Profile in Incident Dialysis PatientsChmielewski M. · Stenvinkel P. · Luttropp K. · Suliman M.E. · Qureshi A.R. · Carrero J.J. · Barany P. · Heimburger O. · Nordfors L. · Lindholm B.
aDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Technology and Intervention, bDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; cDepartment of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland; dFaculty of Medicine, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
Background: Dyslipidemia is a common complication of chronic kidney disease. Lipoprotein lipase (LPL) 1595 C/G and hepatic lipase (HL) –480 C/T single nucleotide polymorphisms (SNPs) influence lipid profile and predisposition for cardiovascular disease in the general population. The present study was undertaken to clarify the impact of the two polymorphisms on lipid parameters and cardiovascular risk in incident dialysis patients. Methods: LPL 1595 C/G and HL –480 C/T SNPs were evaluated in 293 chronic kidney disease patients close to dialysis initiation. Associations with lipid parameters, presence of cardiovascular disease, and survival were assessed. Results: LPL 1595 C/G SNP was associated with significantly lower triglyceride levels [1.55 (1.00–2.20) vs. 1.90 (1.40–2.48) mM; p < 0.01], while HL –480 C/T polymorphism was associated with increased high density lipoprotein cholesterol concentration [1.30 (1.00–1.60) vs. 1.10 (0.90–1.40) mM; p < 0.05]. Neither of the polymorphisms showed any relationship with patient survival. Conclusions: LPL 1595 C/G and HL –480 C/T polymorphisms affect lipid profile in incident dialysis patients.
Michal Chmielewski, MD, PhD
Division of Renal Medicine and Baxter Novum
Department of Clinical Science, Technology and Intervention
Karolinska University Hospital Huddinge, SE–141 86 Stockholm (Sweden)
Tel. +48 609 639 763, Fax +48 583 461 186, E-Mail email@example.com
B.L. is employed by Baxter Healthcare Inc. and P.S. is a member of the Gambro Scientific Advisory Board.
Received: June 26, 2008
Accepted: September 9, 2008
Published online: December 2, 2008
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 3, Number of References : 18
Vol. 26, No. 6, Year 2008 (Cover Date: December 2008)
Journal Editor: Ronco C. (Vicenza)
ISSN: 0253–5068 (Print), eISSN: 1421–9735 (Online)
For additional information: http://www.karger.com/BPU